FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
|Articles|November 2, 2003
- Pharmaceutical Technology-11-02-2003
- Volume 27
- Issue 11
FDA Seeks Risk-Based Inspection Program
Author(s)Jill Wechsler
FDA's new policies intend to make GMP inspections more efficient and apply to stricter rules to high-risk products and processes.
Advertisement
Articles in this issue
almost 23 years ago
FDA Will Drive Changes for Contract Businessalmost 23 years ago
In the Spotlight--Decemberalmost 23 years ago
Novemember 2003almost 23 years ago
Routine Sample Size for a Retest Procedurealmost 23 years ago
November 2003almost 23 years ago
Clearing Regulatory Hurdlesalmost 23 years ago
Improving Protein Capture for Transgenic Drug ProcessingAdvertisement
Related to this article
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
Germany’s Medical Biotechnology Sector is Flourishing
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5